Supporting Information for

Alkali metal mediated hydroboration and cyano sillylation of carbonyl compounds

Adimulam Harinath,^a Jayeeta Bhattacharjee,^a Hari Pada Nayek^b and Tarun K. Panda*^a

Department of Chemistry, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502285, Telangana, India. Fax: + 91(40) 2301 6032; Tel: + 91(40) 2301 6036; E-mail: tpanda@iith.ac.in

Table of Contents

- 1. Table TS1. Crystallographic data and refinement parameters of 1, 3 and 4.
- 2. Figure FS1: ¹H NMR spectra of L1.
- 3. Figure FS2: ¹³C NMR spectra of L1.
- 4. Figure FS3: ¹H NMR spectra of complex **1**.
- 5. Figure FS4: ¹³C NMR spectra of complex 1.
- 6. Figure FS5: ¹H NMR spectra of complex **2**.
- 7. Figure FS6: ¹³C NMR spectra of complex 2.
- 8. Figure FS7: ¹H NMR spectra of complex **3**.
- 9. Figure FS8: ¹³C NMR spectra of complex **3**.
- 10. Figure FS9: ¹H NMR spectra of complex **4**.
- 11. Figure FS10: ¹³C NMR spectra of complex 4.
- 12. Figure FS11: ¹H NMR spectra of complex **5**.
- 13. Figure FS12: ¹³C NMR spectra of complex **5**.
- 14. Figures FS13-FS63: Spectroscopic data of hydroborylation of aldehyde derivatives.
- 15. Figures FS64-FS93: Spectroscopic data of hydroborylation of ketone derivatives.
- 16. Figures FS94-FS114: Spectroscopic data of Selective reduction of carbonyl compounds.
- 17. Figures FS118-FS141: Spectroscopic data of TMSCN addition to carbonyl compounds.
- 18. Figures FS142-FS147: Spectroscopic data of Selective cyanosilylation of carbonyl compounds.
- 19. Figures FS148-FS150: Spectroscopic data of Sequential cyanosilylation and hydroboration of 4-acetylbenzaldehyde.
- 20. Kinetic study.

X-ray crystallographic analyses: Single crystals of complexes 1-4 were grown from a concentrated solution of THF/n-pentane (3:1) in an argon-filled atmosphere at -35 °C. However, single crystals of LH.HCl was obtained from a solution of ethanol at -35 °C. A crystal of suitable dimensions of complexes 1-4 was mounted on a CryoLoop (Hampton Research Corp.) with a layer of light mineral oil and placed in a nitrogen stream at 150(2) K. The crystals of LH.HCl was measured at 298 K. All measurements were made on an Rigaku Supernova X-calibur Eos CCD detector with graphite monochromatic Cu-Ka (1.54184 Å) radiation. The data for the compounds LH.HCl and sodium complex 2 are not satisfactory and R factors are high. Thus only figures of LH.HCl (Fig FS2) and complex 2 (Fig FS3) were used for comparison only. Crystal data and structure refinement parameters of complexes 1, 3 and 4 are summarized in Table TS1. The structures were solved by direct methods (SIR2004)^[1] and refined on F^2 by full-matrix leastsquares methods, using SHELXL-97.^[2] Non-hydrogen atoms were anisotropically refined. Hatoms were included in the refinement on calculated positions riding on their carrier atoms. The function minimized was $[\sum w(Fo^2 - Fc^2)^2] (w = 1 / [\sigma^2 (Fo^2) + (aP)^2 + bP])$, where P = (Max(Fo^2, 0)) $+ 2Fc^2$ / 3 with $\sigma^2(Fo^2)$ from counting statistics. The function R1 and wR2 were ($\Sigma ||Fo| - |Fc||$) / $\Sigma |Fo|$ and $[\Sigma w (Fo^2 - Fc^2)^2 / \Sigma (wFo^4)]^{1/2}$, respectively. The ORTEP-3 program was used to draw the molecules of LH.HCl, 1, 2, and 4. However, Diamond 3 program was used to draw the molecule of **3**. Crystallographic data (excluding structure factors) for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC 1844011 (1), 1844012 (3), 1844010 (4). Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: + (44)1223-336-033; email: deposit@ccdc.cam.ac.uk).



Figure FS1. Molecular solid-state structure of **LH.HCI**. The R factors of the complex **LH.HCI** are slightly high due to poor data set. Nevertheless the Fig FS1 confirms the formation of the ligand **LH**.



Figure FS2. Solid state structure of sodium complex **2**. The R factors of the complex **2** are slightly high due to poor data set. Nevertheless the Fig FS2 confirms the four fold and five fold coordination around the sodium ions.

Crystal	1	3	4
<u>CCDC No</u>	1844011	1844012	1844010
Empirical formula	CasHeaNaLiaOa	C10H27N2OK	C_{4} $H_{70}N_4O_4Mg$
Empirical formula	03811541 (20120)2	C19112/10201K	C4611/01 40 41 19
Formula weight	612.73	338.53	767.37
<i>T</i> (K)	150(2) K 1.54184 A	152(2) K 1.54184 A	150(2) K 1.54184 A
λ (Å)			
Crystal system	monoclinic	triclinic	monoclinic
Space group	$P 2_{1}/c$	P -1	$P 2_1/c$
a(Å)	11.4708(4)	7.3434(12)	11.1013(4)
\dot{b} (Å)	10.5272(3)	11.2646(17)	37,9808(18)
c(Å)	14 4429(4)	11 9562(19)	10 1334(3)
α (°)	90.00	86 178(13)	90.00
$\mathcal{S}(0)$	105 612(3)	72 192(15)	94 (099(3)
$\mathcal{P}(0)$	90.00	76.2192(13)	90.00 00.00
γ (°)	90.00	70.218(14)	90.00
$V(A^3)$	1679.71(9)	914.5(3)	4261.7(3)
Z	2	2	4
$D_{\rm calc} \ { m g} \ { m cm}^{-3}$	1.211	1.229	1.196
$\mu ({\rm mm}^{-1})$	0.567	2.575	0.723
F(000)	664	364	1672
Theta range for	4.001 to 70.59	3.883 to 70.713	3.99 to 70.85 deg.
data collection	Deg	deg	
Limiting indices	$-13 \le h \le 13$,	-8<=h<=8,	-9<=h<=13,
-	$-12 \le k \le 9$,	-7<=k<=13,	-40<=k<=46,
	$-17 \le l \le 13$	- 14<=l<=13.	-11<=l<=12.
Reflections	6112/3151	3359 / 2592	17729 / 8061 [R(int)
collected / unique	[R(int) = 0.0220]	[R(int)] =	= 0.0531]
concerca / unique		0.0349]	0.0001]
Completeness to	99.5 %	76.3 %	98.0 %
theta			
Absorption	Semi-empirical from	Semi-empirical	Semi-empirical from
corraction	equivalents	from equivalents	equivalents
Max. and min.	1.00000 and	1.00000 and	1.00000 and 0.65420
transmission	0.68112	0.83710	
Refinement	Full-matrix least-	Full-matrix	Full-matrix least-
method	squares on F ²	least-squares on F^2	squares on F ²
Data / restraints / parameters	3151 / 0 / 216	2592 / 0 / 215	8061 / 0 / 496
Goodness-of-fit on F ²	1.123	1.084	1.047

 Table TS1. Crystallographic data and refinement parameters of 1, 3 and 4.

Final R indices	R1 = 0.0475,	R1 = 0.0732,	R1 = 0.0738, wR2 =
[I>2sigma(I)]	wR2 = 0.1388	wR2 = 0.1893	0.1870
R indices (all data)	R1 = 0.0511,	R1 = 0.0957,	R1 = 0.0976, wR2 =
	wR2 = 0.1413	wR2 = 0.2186	0.2089
Absolute structure parameter			
Largest diff. peak and hole	0.267 and -0.305 e.A^-3	0.683 and -0.666 e.A^-	0.550 and -0.359 e.A^-3



Figure FS4. ¹³C NMR spectra of complex L1.









Figure FS6. ¹³C NMR spectra of complex 1.



Figure FS8. ¹³C NMR spectra of complex 2.



Figure FS9: ¹H NMR spectra of complex 3.



Figure FS10. ¹³C NMR spectra of complex 3.



Figure FS11. ¹H NMR spectra of Magnesium complex 4.



Figure FS12. ¹³C NMR spectra of magnesium complex 4.



Figure FS13. ¹H NMR spectra of calcium complex 5.



Figure FS14. ¹³C NMR spectra of Calcium complex 5.

Typical procedure for hydroborylation of carbonyl compounds:

Hydroboylation of carbonyl compounds were carried out using the following standard protocol. In the glove box, the chosen pre-catalyst (0.03 mmol) was loaded into a Schlenk tube, and subsequently the aldehyde or ketone (1 mmol) followed by pinacolborane (1 mmol) were added. The reaction was stirred in an oil bath at the desired temperature (30°C). Substrate conversion was monitored by examination of the ¹H NMR, which indicates the formation of new CH_2 (for aldehydes) CH (ketones) peak and disappearance of aldehyde proton.

Typical procedure for TMSCN addition to carbonyl compounds:

TMSCN addition of carbonyl compounds were carried out using the following standard protocol. In the glove box, the chosen pre-catalyst (0.03 mmol) was loaded into a Schlenk tube, and subsequently the aldehyde or ketone (1 mmol) followed by TMSCN (1 mmol) were added. The reaction was stirred in an oil bath at the desired temperature (30° C).



Figure FS15. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure S16. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2dioxaborolane.



Figure FS17. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2dioxaborolane.



Figure FS18. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-((4-methoxybenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane.



Figure S19. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-((4-methoxybenzyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS20. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-((4-methoxybenzyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS21. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-((4-isopropylbenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane.



Figure S22. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-((4-isopropylbenzyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS23. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-((4-isopropylbenzyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS24. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-((2,4,6-trimethoxybenzyl)oxy)-1,3,2-dioxaborolane.



Figure S25. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-((2,4,6-trimethoxybenzyl)oxy)-1,3,2-dioxaborolane.



Figure FS26. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-((2,4,6-trimethoxybenzyl)oxy)-1,3,2-dioxaborolane.



Figure FS27. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-((4-fluorobenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane.



Figure S28. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-((4-fluorobenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane



Figure FS29. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-((4-fluorobenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane.



Figure FS30. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-((4-bromobenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane.



Figure S31. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-((4-bromobenzyl)oxy)-4,4,5,5tetramethyl-1,3,2-dioxaborolane.



Figure FS32. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-((4-bromobenzyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS33. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-((4-nitrobenzyl)oxy)-1,3,2-dioxaborolane.



Figure S34. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-((4-nitrobenzyl)oxy)-1,3,2-dioxaborolane.



Figure FS35. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-((4-nitrobenzyl)oxy)-1,3,2-dioxaborolane.



Figure FS36. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of (E)-4,4,5,5-tetramethyl-2-(styryloxy)-1,3,2-dioxaborolane.



Figure S37. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of (E)-4,4,5,5-tetramethyl-2-(styryloxy)-1,3,2-dioxaborolane.



Figure FS38. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of (E)-4,4,5,5-tetramethyl-2-(styryloxy)-1,3,2-dioxaborolane.



Figure FS39. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)benzonitrile.



Figure S40. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)benzonitrile.



Figure FS41. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)benzonitrile.



70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 Chemical Shift (ppm)

Figure S43. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)phenol.





Figure FS45. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)phenol.



Figure S46. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)phenol.



Figure S47. ¹³C NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)phenol.



Figure FS48. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)pyridine.



Figure S49. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)pyridine.



Figure FS51. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(thiophen-2-ylmethoxy)-1,3,2-dioxaborolane.



Figure S52. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(thiophen-2-ylmethoxy)-1,3,2-dioxaborolane.



Figure FS53. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(thiophen-2-ylmethoxy)-1,3,2-dioxaborolane.



60 55 50 45 40 35 30 25 20 15 10 5 Chemical Shift (ppm)

Figure S55. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-pyrrole.



Figure FS56. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-pyrrole.



Figure FS57. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 3-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-indole.



Figure S58. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 3-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-indole.



Figure FS59. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 3-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-indole.



Figure FS60. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2,5-bis(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-pyrrole.



Figure S61. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2,5-bis(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-pyrrole.



Figure FS62. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2,5-bis(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)-1H-pyrrole.



Figure FS63. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-ferrocenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.


Figure S64. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-ferrocenyl-4,4,5,5-tetramethyl-1,3,2dioxaborolane.



Figure FS65. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-ferrocenyl-4,4,5,5-tetramethyl-1,3,2dioxaborolane.



Figure FS66. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(benzhydryloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure S67. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(benzhydryloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS68. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(benzhydryloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS69. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(1-phenylethoxy)-1,3,2-dioxaborolane.



Figure S70. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(1-phenylethoxy)-1,3,2-dioxaborolane.



Figure FS71. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(1-phenylethoxy)-1,3,2-dioxaborolane.



Figure FS72. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(1-(p-tolyl)ethoxy)-1,3,2-dioxaborolane.



Figure S73. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(1-(p-tolyl)ethoxy)-1,3,2-dioxaborolane.



Figure FS74. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4,4,5,5-tetramethyl-2-(1-(p-tolyl)ethoxy)-1,3,2-dioxaborolane.



Figure FS75. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(1-(2-chlorophenyl)ethoxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure S76. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(1-(2-chlorophenyl)ethoxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS77. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(1-(2-chlorophenyl)ethoxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.



Figure FS78. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure S79. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure FS80. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure FS81. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 3-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure S82. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 3-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure FS83. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 3-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure FS84. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 4-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure S85. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 4-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure FS86. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 4-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)ethyl)aniline.



Figure FS87. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(phenyl((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)aniline.



Figure S88. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 2-(phenyl((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)aniline.



Figure FS89. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(phenyl((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)aniline.



Figure FS90. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 1,2-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)-1,2-dihydroacenaphthylene.



Figure S91. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 1,2-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)-1,2-dihydroacenaphthylene.



Figure FS92. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 1,2-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)-1,2-dihydroacenaphthylene.



Figure FS93. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 1,2-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)-1,2-dihydroacenaphthylene.



Figure S94. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of 1,2-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)-1,2-dihydroacenaphthylene.



Figure FS95. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 1,2-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)-1,2-dihydroacenaphthylene.



Figure FS96. ¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of aldehydes.



Figure FS97. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of aldehydes.



Figure FS98. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction of aldehyde.



Figure FS99. ¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of aldehydes.



Figure FS100. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of aldehydes.



Figure FS101.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction of aldehyde.



Figure FS102.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of aldehydes.



Figure FS103. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of aldehydes.



Figure FS104.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction of aldehyde.



Figure FS105.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of aldehydes.



Figure FS106. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of aldehydes.



Figure FS107.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction of aldehyde.



Figure FS108.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of aldehydes.



Figure FS109. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of aldehydes.



Figure FS110.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction of aldehyde.



Figure FS111.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of aldehydes.



Figure FS112. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of aldehydes.



Figure FS113.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction of aldehyde.



Figure FS114.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective reduction of 16dehydropregnolone acetate.



Figure FS115. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of Chemo selective reduction of 16dehydropregnolone acetate.



Figure FS116.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) Chemo selective reduction 16dehydropregnolone acetate.



Figure FS117.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of complex **3** in presence of excess *p*-OMe Benzaldehyde



Figure FS118.¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of complex 3 in presence of excess HBpin.



Figure FS119. ¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of complex **3** in presence of excess HBpin.



Figure FS120. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-phenyl-2 ((trimethylsilyl)oxy)acetonitrile.



Figure FS121. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-phenyl-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS122. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(4-methoxyphenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS123. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(4-methoxyphenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS124. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(4-isopropylphenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS125. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(4-isopropylphenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS126. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(2,4,6-trimethoxyphenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS127. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(2,4,6-trimethoxyphenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS128. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(4-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS129. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(4-fluorophenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS130. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(4-bromophenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS131. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(4-bromophenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS132. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(2-nitrophenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS133. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(2-nitrophenyl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS134. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(1H-pyrrol-2-yl)-2-((trimethylsilyl)oxy)acetonitrile.



Figure FS135. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(1H-pyrrol-2-yl)-2-((trimethylsilyl)oxy)acetonitrile.


Figure FS136. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(1H-indol-3-yl)-2- ((trimethylsilyl)oxy)acetonitrile.



Figure FS137. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(1H-indol-3-yl)-2- ((trimethylsilyl)oxy)acetonitrile.



((trimethylsilyl)oxy)propanenitrile.



Figure FS140. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(p-tolyl)-2- ((trimethylsilyl)oxy)propanenitrile.



((trimethylsilyl)oxy)propanenitrile.



Figure FS142. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2-(2-nitrophenyl)-2-((trimethylsilyl)oxy)propanenitrile.



Figure FS143. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2-(2-nitrophenyl)-2-((trimethylsilyl)oxy)propanenitrile.



Figure FS144. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of 2,2'-(1H-pyrrole-2,5-diyl)bis(2-((trimethylsilyl)oxy)acetonitrile).



Figure FS145. ¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of 2,2'-(1H-pyrrole-2,5-diyl)bis(2-((trimethylsilyl)oxy)acetonitrile).



Figure FS146.¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of chemo selective cyanosilylation of aldehydes.



Figure FS147.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of Chemo selective cyanosilylation of aldehydes.



Figure FS148. ¹H NMR spectrum (400 MHz, 25°C, CDCl₃) of chemo selective cyanosilylation of aldehydes.



Figure FS149. ¹³C NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective cyanosilylation of aldehydes.



Figure FS150. ¹H NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective cyanosilylation of aldehydes.



Figure FS151. ¹³C NMR spectrum (128.4 MHz, 25°C, CDCl₃) of chemo selective cyanosilylation of aldehydes.



Figure FS152. ¹H NMR spectrum (400MHz, 25°C, CDCl₃) of sequential cyanosilylation and hydroboration of 4-acetyl benzaldehyde.



Figure FS153.¹¹B NMR spectrum (128.4 MHz, 25°C, CDCl₃) of sequential cyanosilylation and hydroboration of 4-acetyl benzaldehyde.



Figure FS154.¹³C NMR spectrum (100 MHz, 25°C, CDCl₃) of sequential cyanosilylation and hydroboration of 4-acetyl benzaldehyde.

References:

- A. Altomare, M. C. Burla, G. Camalli, G. Cascarano, C. Giacovazzo, A. Guagliardi and G. Polidori, *J. Appl. Crystallogr*. 1994, 27, 435-436.
- 2. G. M. Sheldrick, Acta Crystallogr. Sect. A: 2008, A64, 112-122.
- 3. V. L. Weidner, C. J. Barger, M. Delferro, T. L. Lohr, T. J. Marks, ACS Catal. 2017, 7, 1244.
- 4. S. Chen, D. Yan, M. Xue, Y. Hong, Y. Yao, Q. Shen, Org. Lett. 2017, 19, 3382.
- 5. W. Yohsuke, Y. Takashi, J. Org. Chem. 2011, 6, 1957-1960.
- Y. Li, J.Wang, Y. Wu, H Zhu, P. P. Samuel, H. W. Roesky, *Dalton Trans.* 2013, 42, 13715– 13722.
- 7. D. Martin, M. Soleilhavoup, G. Bertrand, Chem. Sci. 2011, 2, 389 399.
- 8. M. Asay, C. Jones, M. Driess, Chem. Rev. 2011, 111, 354 396.